Tag: RSH

Respiri raises placement commercialise wheezo asthma device ASX RSH

Respiri raises $12.5 million to commercialise wheezo asthma device

eHealth company Respiri (ASX: RSH) has completed a $12.5 million capital raising targeted at the commercial launch of its proprietary wheezo asthma management platform in Australia before year end. ...
Respiri ASX RSH Entech Electronics wheezo

Respiri engages Entech Electronics to manufacture wheezo at ‘significantly’ improved cost

Health technology company Respiri (ASX: RSH) has engaged Entech Electronics to manufacture its “ground breaking” wheezo device offshore in China, which is expected to “significantly improve” productio...
Respiri wheezo clinical study results ASX RSH 2020

Respiri unveils promising wheezo clinical study results

Preliminary results of a clinical study involving the wheezo asthma management platform made by eHealth technology developer Respiri (ASX: RSH) has shown the device is capable of accurately detecting ...
Respiri ASX RSH Carlton Football Club AFLW Team womens wheezo

Respiri teams up with Carlton Football Club to promote wheezo device

A day after publishing its full year accounts, eHealth company Respiri (ASX: RSH) has tentatively set foot in Australian rules football courtesy of a partnership with Carlton Football Club AFLW, comme...
Respiri ASX RSH Australian Patients Association APA asthma wheezo

Respiri signs referral agreement with APA to proliferate wheezo in Australia

eHealth company Respiri (ASX: RSH) has taken another step towards growing sales of its wheezo device ahead of its October launch, after signing a three-year product referral agreement (PRA) with the A...
Respiri ASX RSH Australian Patients Association wheezo real world study

Respiri partners with Australian Patients Association for wheezo study

eHealth Software-as-a-Service (Saas) company Respiri (ASX: RSH) has updated the market with news it has entered into a partnership with the Australian Patients Association (APA) to support asthma suff...
Respiri ASX RSH wheezo revenue 2021 Software as a Service SaaS

eHealth SaaS provider Respiri targets $6-8m revenue for 2021

eHealth technology developer and maker of the wheezo device, Respiri (ASX: RSH) has published interim revenue guidance for 2021 with total revenues from both device and software subscription estimated...
Respiri ASX RSH wheezo BNPL Zip

Respiri accelerates wheezo commercialisation by teaming up with BNPL company Zip

Wheezo developer Respiri’s (ASX: RSH) commercialisation path will accelerate even further after the company collared a deal with renowned buy now pay later provider Zip Co Ltd (ASX: Z1P). Respiri c...
Respiri Wheezo ASX RSH sales distribution Cipla Australia

Respiri secures global sales and distribution agreement for wheezo asthma monitoring device

Healthcare technology developer Respiri (ASX: RSH) has signed an exclusive agreement with global respiratory pharmaceutical firm Cipla for the sales and distribution of Respiri’s wheezo asthma product...
Respiri eHealth SaaS Company Wheezo Health Data Research Hub for Respiratory Health HDR UK ASX RSH

Respiri partners with UK data research centre in preparation for Wheezo’s EU launch

eHealth software company Respiri (ASX: RSH) has unveiled a new partnership agreement with the University of Edinburgh to feed data from its proprietary Wheezo devices into a new data research centre i...
Respiri ASX RSH wheezo Pharmacy Guild of Australia market potential agreement

Respiri grows wheezo market potential through agreement with the Pharmacy Guild of Australia

Respiri (ASX: RSH) has collared a two-year definitive service agreement with the Pharmacy Guild of Australia to develop an online pharmacist course on optimising asthma patient management including th...
Respiri Share Purchase Plan SPP ASX RSH Wheezo

Shareholders back Respiri in heavily oversubscribed share purchase plan

Respiri (ASX: RSH) has topped up its cash reserves with $3.14 million after receiving “significant oversubscriptions” in a recent share purchase plan. The company launched the share purchase plan l...
Respiri telehealth GPNow ASX RSH Practice Innovators International respiratory asthma

Respiri strikes telehealth deal with Aussie start-up to improve respiratory care for asthma patients

Respiratory health management company Respiri (ASX: RSH) has entered into commercial discussions with Australian start-up Practice Innovators International Pte Ltd with a view to launching an integrat...
Respiri wheezo telehealth market Phenix Health ASX RSH

Respiri expands wheezo into telehealth market with Phenix partnership

Respiri (ASX: RSH) has expanded the market for its wheezo technology after announcing a partnership with Phenix Health. The parties have inked a joint development agreement which will involve integ...
Respiri coronavirus COVID19 China Wheezo ASX RSH

Respiri experiences requests for wheezo devices to monitor COVID-19 patients in China

Respiratory focused SaaS company Respiri (ASX: RSH) has experienced inbound demand for its wheezo technology from three Chinese hospitals relating to monitoring patients with coronavirus COVID19...
Respiri Wheezo ASX RSH CE Mark TGA approval

Respiri’s Wheezo product approved for sale following CE Mark and TGA registration

Healthcare technology developer Respiri (ASX: RSH) has revealed that the company has received the highly coveted CE Mark and TGA approval to list its Wheezo product on the Australian Therapeutics Good...
Bruce Thompson Respiri ASX RSH asthma

Appointment of professor Bruce Thompson provides Respiri clinical credibility

Bruce Thompson has been appointed as chair of Respiri’s (ASX: RSH) Australian medical and scientific Advisory board and product portfolio development lead. Bruce Thompson is Professor of Allergy, I...
Respiri ASX RSH SRX Global wheeze asthma

Respiri appoints SRX Global to manufacture wheeze and asthma sensor

Respiri (ASX: RSH) has ticked off another key milestone – a manufacturing agreement with SRX Global, to produce its next generation breath and asthma wheeze detection sensor. The sensor is the hard...
Respiri wheeze monitoring device AirSonea asthma management RSH

Respiri’s wheeze monitoring device to improve asthma management

Healthcare technology developer Respiri (ASX: RSH) is in the final stages of commercialising its asthma monitoring product called AirSonea. It will be a major boost for asthma sufferers worldwide, ...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS